Close menu

November 17th, 2022 | 10:40 CET

Breaking news drives Nel ASA share: What are BioNTech and Kleos Space up to?

  • Space
  • Biotechnology
Photo credits:

Growth stocks are currently celebrating a comeback. In particular, when there is also positive news from the company itself, as is the case with Nel ASA. The share of the hydrogen specialist increased by 40% within 4 weeks, and analysts see further potential for their "Top Pick". And then the Norwegians announced a cooperation with General Motors yesterday. BioNTech is also looking good from a chart and operational point of view. The cash box is full, allowing the Mainz-based company to increase production capacities. There is also something happening with space stocks. The valuation of Elon Musk's SpaceX is said to have risen by USD 25 billion in the latest round of financing, which should also improve the environment for Kleos Space. The specialist in space-based high-frequency reconnaissance is facing important weeks.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , NEL ASA NK-_20 | NO0010081235 , KLEOS SPACE CDI/1/1 | AU0000015588

Table of contents:

    Kleos Space: Will the stock still take off in 2022?

    While BioNTech and Nel have already moved well away from the low for the year, Kleos Space is still waiting for the countermovement. But this could be imminent. A SpaceX rocket is to be launched this year. On board: The fourth satellite cluster from Kleos Space. The cluster has passed all tests and is on its way to Elon Musk's SpaceX. Full commissioning will then take place by mid-2023. Three satellite clusters are already in space and are expected to be in formation this month. Accordingly, Kleos Space can start generating revenue. As a result, the shares of the specialist for space-based high-frequency reconnaissance could soon take off. The Company hopes to receive orders from the US government in the future. Initial test projects are already underway. According to analysts, Kleos Space should multiply its sales in the coming years.

    Analysts at First Berlin expect Kleos to increase sales from EUR 2.20 million in the current year to EUR 12.50 in the coming year. In 2024, this figure should then already be EUR 20.20 million. Then, a net profit of at least EUR 2 million should be achieved for the first time. With a current market capitalization of AUD 40 million, the price/earnings ratio for 2024 is just over 13. Not too much for a company in an industry of the future. Therefore, First Berlin recommends Kleos shares as a buy with a price target of AUD 1.60 (to the full report

    Nel: Bringing GM on board

    Nel's stock is still a few years away from a price-to-earnings ratio. Operating performance has disappointed this year. Nevertheless, Jefferies analysts consider the Norwegian company's stock the "Top Pick" in the hydrogen sector. They say the current order backlog makes it easy to plan for sales development until mid-2024. They, therefore, recommend Nel shares as a buy with a target price of NOK 19. But this is not the only thing Nel shareholders can be happy about. The Company is also making progress strategically. For example, the Norwegians announced a cooperation with General Motors (GM) yesterday. By combining GM's fuel cell expertise with Nel's hydrogen know-how, the partners aim to significantly reduce green hydrogen production costs.

    By combining GM's extensive fuel cell expertise and Nel's decades of knowledge in electrolyzers, the two companies aim to develop more competitive sources of renewable hydrogen. "General Motors is one of the world leaders in hydrogen fuel cell propulsion with more than 50 years of experience," said Nel CEO Håkon Volldal. "We believe this collaboration will give us a competitive advantage in industrializing the production of our PEM electrolyzers and further improving the efficiency of our technology." GM management also has high hopes for the partnership. For example, GM's fuel cell expertise is expected to help Nel scale. GM would receive payments for development work and the transfer of intellectual property. In addition, royalty payments are planned after successful product development, he said.

    BioNTech: Expand into Asia

    The BioNTech share has also performed well in recent weeks, with the share now trading at EUR 160 again. UBS believes that the share price potential has been exhausted for the time being. Although BioNTech published strong figures for the third quarter, sales and profits in the coming year are difficult to plan. Therefore, the analysts rate the shares of the Mainz-based company as "neutral" with a price target of USD 168.

    Operationally, meanwhile, BioNTech continues to go full throttle. The Mainz-based company has purchased a GMP-certified production facility in Singapore from pharmaceutical giant Novartis. The fully integrated mRNA production facility is expected to be operational by the end of 2023. In addition to mRNA for vaccines, it will also be able to produce oncology therapies in ready-to-fill batches. "The acquisition will allow us to accelerate the build-out of a state-of-the-art mRNA manufacturing facility, providing faster capacity for potential clinical trials and commercial delivery of our mRNA vaccines and therapeutics in the region. Over the coming months, we will work closely with all parties involved to ensure a smooth handover of the facility and prepare for the start of production," said Sierk Poetting, chief operating officer of BioNTech. The new manufacturing facility will also serve as the regional headquarters.

    Kleos Space's stock could take off this year. BioNTech has numerous trial results coming up in the next year. Nel needs to continue to grow into its high valuation.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on March 23rd, 2023 | 08:02 CET

    BioNxt Solutions, Bayer, BioNTech - These pharma stocks offer growth potential

    • Biotechnology
    • research
    • Pharma

    The risk of cancer is increasing worldwide for people over the age of 50. The reasons for this are lack of sleep and exercise, pre-existing diseases and poor nutrition. It has now also been scientifically proven that permanent stress is a cause of Parkinson's disease. According to the WHO, disabilities and deaths due to Parkinson's are increasing faster worldwide than for any other neurological disease. Pharmaceutical and biotech companies are doing everything they can to improve the quality of life of those affected. The Canadian biotech company BioNxt is working on a comparative study to improve a therapy patch for treating Parkinson's and make accompanying drug products scalable. Bayer subsidiary Bluerock Therapeutics is using data from the Apple Watch to research Parkinson's symptoms. And CEO Uğur Şahin of BioNTech has closed a billion-dollar deal in cancer therapy.


    Commented by Stefan Feulner on March 20th, 2023 | 09:37 CET

    Evotec, Defence Therapeutics, Morphosys - Movement in the biotech sector

    • Biotechnology
    • Investments

    Is a new wave of takeovers starting in the biotech sector? Already last year, acquisitions by Big Pharma were expected to increase, but these largely failed to materialize. However, this could accelerate in the current year. On the one hand, pharmaceutical companies, such as vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio; on the other hand, second-tier stocks are attractive targets due to the strong correction.


    Commented by Fabian Lorenz on March 16th, 2023 | 11:51 CET

    Takeover speculation at Defence Therapeutics! What are BioNTech, Morphosys, and Evotec doing?

    • Biotechnology
    • Takeover

    Defence Therapeutics is one of the biotech high flyers of the past months. The share has more than doubled since October. And this could be just the beginning. Operationally, things are going well, a strong partner has been acquired, and experts are speculating about a takeover. And what are the German biotechs doing? At BioNTech, it will be exciting at the end of March, because the Mainz-based company needs new blockbusters. At Morphosys, analysts recently saw further downside potential. Will a new management board bring about a turnaround? Evotec also had little positive to report. However, an AI investment in the hype surrounding ChatGPT is making headlines.